Wed, Apr 26, 2017
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Barclay Hedge Fund Index slips 0.29% in January; Healthcare & Biotechnology opens 2014 with 5.97% gain

Wednesday, February 19, 2014
Opalesque Industry Update - Hedge funds lost 0.29% in January, according to the Barclay Hedge Fund Index compiled by BarclayHedge. The Index gained 11.11% in 2013.

“After a rousing end to 2013, January bore witness to a complete reversal of key trends as investor sentiment turned defensive,” says Sol Waksman, founder and president of BarclayHedge.

“Global equity markets sold off as emerging markets came under renewed pressure from slowing in China, political unrest in Thailand and Turkey, and currency devaluation in Argentina." Overall performance by hedge fund sector was mixed in January. Twelve of Barclay’s 18 hedge fund indices had gains, while six indices had losses.

The Barclay Healthcare & Biotechnology Index jumped 5.97% in January, its largest one-month return since posting a gain of 6.27% in May of 2009.

“The Healthcare sector was a beneficiary of the move by investors out of cyclical stocks and into defensive stocks,” says Waksman.

The Barclay Equity Short Bias was up 1.95% in January, Distressed Securities gained 1.55%, European Equities were up 1.20%, Convertible Arbitrage gained 1.10%, and Fixed Income Arbitrage rose 0.94%.

In contrast, the Emerging Markets Index lost 2.47%, Pacific Rim Equities were down 0.96%, Equity Long Bias gave up 0.86%, anf Global Macro lost 0.55%.

The Barclay Fund of Funds Index was down 0.36% in January.

BarclayHedge

Press Release

BM

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Alternative asset firm YieldStreet surpasses $100m of loans funded in less than 8 quarters[more]

    Komfie Manalo, Opalesque Asia: Alternative asset investment platform YieldStreet reported that it has surpassed $100m in loans funded in less than eight quarters from accredited investors and single family offices. YieldStreet was founded by Milind Mehere and Michael Weisz. In a

  2. Investing - Investor appetite for high-growth IPOs to be tested, Apollo boosts fund's stock allowance for 'diamonds in the rough', Hedge funds uncertain over outlook for Hargreaves Lansdown[more]

    Investor appetite for high-growth IPOs to be tested From FT.com: The US listings market is poised for a busy week with deals that will test investors' appetite for high-growth - but lossmaking - companies. Eight new listings are scheduled for this week, the most since October of 2016,

  3. Hedge funds holding Puerto Rico bonds are looking at a long battle[more]

    Komfie Manalo, Opalesque Asia: Hedge funds which bought Puerto Rico's distressed debt bonds are facing the prospect of a long road ahead to recover their investments as the Caribbean island is attempting to use a U.S. Congress-approved rule that allows it to exploit a bankruptcy-like proceedings

  4. Other Voices: "Winner-take-all" dynamics and hedge fund investing[more]

    A growing stream of thinking in microeconomics is the concept of "winner-take-all" dynamics. The idea seems simple. A combination of networking economics and classic economies of scale creates situations where there are just a few dominant firms or economic agents who are able to capture significant

  5. Investing - How Chipotle's comeback attracted big data robots and value investors alike[more]

    From Forbes.com: When William Ackman's ailing hedge fund Pershing Square Capital Management bet $1 billion on shares in Chipotle Mexican Grill beginning in July 2016, the stakes couldn't have been higher. Pershing Square was reeling from what would eventually be a near $4 billion loss in drugmaker V